Decreased Expression of the CD57 Molecule in T Lymphocytes of Patients with Chronic Fatigue Syndrome.
Espinosa, P, Urra, J M · Molecular neurobiology · 2019 · DOI
Quick Summary
Researchers measured levels of a protein called CD57 on immune cells in ME/CFS patients and compared them to healthy people. They found that ME/CFS patients had significantly lower amounts of CD57 on their T cells (a type of white blood cell). This difference was large enough that measuring CD57 levels could potentially help doctors diagnose ME/CFS.
Why It Matters
ME/CFS currently lacks objective biological markers for diagnosis, making this study important as it identifies a measurable immune abnormality that could support clinical diagnosis. If validated in larger studies, CD57 measurement could provide clinicians with a blood test to objectively confirm ME/CFS, reducing diagnostic delay and improving patient access to appropriate care.
Observed Findings
T lymphocyte CD57 expression (percentage) was lower in ME/CFS patients (7.5% ± 1.2) compared to controls (13.3% ± 1.6), p=0.024
T lymphocyte CD57 density per cell was substantially lower in ME/CFS patients (331 ± 59) versus controls (1003 ± 104), p≤0.0001
Non-T lymphocyte CD57 density was reduced in ME/CFS patients (379 ± 114) compared to controls (691 ± 95), p=0.007
CD57 expression changes were most pronounced in T lymphocytes rather than other lymphocyte populations
Inferred Conclusions
CD57 expression is reduced in ME/CFS patients across multiple lymphocyte subsets, with T lymphocytes showing the most significant abnormalities.
CD57 measurement, particularly in T lymphocytes, may serve as a useful diagnostic biomarker for ME/CFS.
Both the percentage of CD57-expressing cells and the amount of CD57 per cell contribute to distinguishing ME/CFS patients from healthy controls.
Remaining Questions
Does CD57 reduction reflect immune aging, exhaustion, or a specific ME/CFS-related immune dysfunction mechanism?
How do CD57 levels correlate with ME/CFS disease severity, symptom patterns, or treatment response?
Are CD57 changes present in early disease stages, and can they predict long-term outcomes?
What This Study Does Not Prove
This study does not prove that low CD57 causes ME/CFS or explain the mechanism behind this immune abnormality. As a cross-sectional study, it only shows an association at one time point and cannot establish whether CD57 changes precede, follow, or contribute to disease development. Findings require replication in independent populations before clinical implementation.